Clinical Trial Update: A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients [Phase 4]

View source ↗

Summary

A Phase 4 pilot trial evaluated whether lowering parathyroid hormone reduces erythropoietin consumption in calcitriol-resistant patients with secondary hyperpar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease Stage
• Hyperparathyroidism

Drugs mentioned

• Parathyroid hormone lowering intervention

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Moderate to Severe Secondary Hyperparathyroidism, Stage 5 Chronic Kidney Diseases | Phase 4 | Status: COMPLETED | Results posted: 2017-05-15